ADB-P7AICA.

ADB-P7AICA is a 7-azaindole (pyrrolo[2,3-b]pyridine) 3-carboxamide combining a tert-leucinamide head and an N-pentyl chain. The only published pharmacological characterisation is that of Sparkes et al. (RSC Medicinal Chemistry, 2022): by displacement of [³H]CP55,940 on HEK293 membranes, a Ki of 3.94 nM at CB1 and 20.4 nM at CB2; by membrane potential in AtT20 cells, an EC50 of 5.8 nM at CB1 and 7.1 nM at CB2, for a maximal effect reaching 112 % and 108 % of that of CP55,940. It is therefore a high-efficacy agonist at both receptors, where THC is only a partial agonist. The authors place the 7-azaindole core well behind the indazoles, ADB-BUTINACA tested in parallel binding CB1 with a Ki of 0.299 nM, more than ten times better. In β-arrestin 2 recruitment (NanoBiT, HEK293T cells), the EC50 at CB1 falls back to 147 nM. In mice, the molecule lowers core body temperature at 10 mg/kg, the signature of a central cannabimimetic action (ADB-BUTINACA acts from 0.1 mg/kg). Beyond this single paper and the DEA announcement of February 2021, the literature is empty: no clinical case, no metabolism study, no human data.

Source

A synthetic product with no natural occurrence: a laboratory molecule distributed as a designer drug. It was spotted in the United States by the Drug Enforcement Administration together with the CTEB clinical toxicology laboratory of the University of California, San Francisco, in urine samples collected in November 2020 from a group of detainees in Alabama.

No biosynthetic pathway: the molecule does not exist in hemp and comes from laboratory synthesis.

European Union

No European Union act names ADB-P7AICA: a EUR-Lex search returns no result, and the molecule has not been the subject of a risk assessment followed by a control measure at Union level. Control rests with national laws: Germany covers it through the generic cannabimimetics group of annex 1 of the NpSG, which expressly targets the 7-azaindol-1,3-diyl motif with a carboxamide bridge. Outside the Union, the United Kingdom places it in Class B through the generic clause of 2016, which explicitly cites the pyrrolo[2,3-b]pyridine core, the carboxamide bridge and an alkyl chain. No international control measure under the United Nations conventions has been identified. A close analogue, 5F-AB-P7AICA, had been notified to the Union's Early Warning System by Germany in 2018; that notification concerns the analogue, not this molecule.

France

Not classified by name. France classifies synthetic cannabinoids by generic families in annex IV of the decree of 22 February 1990, recast by the decree of 31 March 2017 (twelve skeleton families in 2017; a thirteenth, the benzo[c]chromene family, was added in 2024). ADB-P7AICA does not appear there, and its pyrrolo[2,3-b]pyridine (7-azaindole) core is not covered, since the only azaindole family retained is that of the "pyrrolo[3,2-c]pyridine carboxamide", a different fusion isomer. The ANSM consolidated list (updated 16 February 2026) contains neither that term nor the name ADB-P7AICA; it does, however, name other 7-azaindole cannabinoids, CUMYL-P7AICA and 5F-CUMYL-P7AICA (decision of 22 May 2024). As the text stands, the molecule is therefore caught neither by a listing by name nor by a generic clause, a situation liable to change with each amendment of annex IV.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

7-azaindole-3-carboxamide (pyrrolo[2,3-b]pyridine)

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

ADB-P7AICA (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

1. 1Sparkes et al. · RSC Medicinal Chemistry 2022 (SAR ADB-BUTINACA, APP-BUTINACA, ADB-P7AICA) (new tab)PMID 35308023
2. 2DEA Toxicology Testing Program, Announcement of a Newly Identified Synthetic Cannabinoid ADB-P7AICA, 25 February 2021 (urines of Alabama inmates from November 2020, CTEB laboratory of the University of California, San Francisco; no pharmacological data at that date) (new tab)
3. 3Order of 31 March 2017 amending the order of 22 February 1990, Annex IV (Légifrance) (new tab)
4. 4NpSG, annex 1, cannabimimetics group (Germany) (new tab)
5. 5Misuse of Drugs Act 1971 (Amendment) Order 2016 (United Kingdom) (new tab)
6. 6PubChem CID 155538637 (new tab)
7. 7ACMD, Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists, Home Office, 2023: effects described for the class of synthetic agonists (new tab)

SMILES

NC(=O)[C@@H](NC(=O)c1cn(CCCCC)c2ncccc21)C(C)(C)C

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.